Content not found ...
Professor of Respiratory Medicine at Queen’s University Belfast, Northern Ireland
Professor Liam Heaney is Professor of Respiratory Medicine at Queen’s University Belfast, N. Ireland, who trained in Northern Ireland and in the Royal Brompton Hospital in London. He is Director of the Northern Ireland Regional Difficult Asthma Service which over the past 10 years has developed a programme of optimal clinical assessment in this population including multi-disciplinary systematic assessment and identification and management of poor adherence. He has chaired the British Thoracic Society Specialist Advisory Group for Asthma, the Evidence Review Group for Difficult Asthma for the British Thoracic Society / Scottish Intercollegiate Guideline on Asthma Management and has been a member of the National Steering Committee for the UK Asthma Guidelines. He co ordinates the UK Severe Asthma Registry and NICE UK Thermoplasty Registry. He is Academic Lead of the Medical Research Council UK Refractory Stratification Programme (http://www.rasp.org.uk) and has published extensively on the clinical assessment and management of difficult-to-control asthma in adults
Professor of Respiratory Medicine at the South Paris University (Université Paris-Saclay) in Le Kremlin-Bicêtre, France
Director of the French Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France
Marc Humbert, MD, PhD, is Professor of Respiratory Medicine at the South Paris University (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities, he is the Director of the French Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris. Along with membership to several scientific councils and institutes, Marc Humbert is the current Director of the INSERM Unit “Pulmonary Hypertension: Pathophysiology and Innovative Therapies” and of the “Thorax Innovation” University Hospital Department. He was the Chief Editor of the European Respiratory Journal from 2013 to 2017. He has published over 700 peer-reviewed articles, mostly in the field of pulmonary hypertension. He is a Fellow of the European Respiratory Society (FERS Foundation Fellow) and has received several distinctions including the 1997 François Brenot Award and the 2006 Cournand Lecture Award from the ERS, the 2009 Descartes-Huygens Award from the Royal Netherlands Academy of Arts and Sciences, the 2016 Rare Disease Award of the Fondation de France (Fondation Eliane and Gérard Pauthier), and the 2018 ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension. Since 2017, Marc Humbert has been the vice-coordinator of the European Reference Network for rare and low prevalence respiratory diseases (ERN-LUNG).
Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, UK
Professor Wisia Wedzicha is Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UK and Head of the Division of Airways Disease. She qualified from Somerville College, Oxford University and St Bartholomew’s Hospital Medical College, University of London. She was elected as Fellow of the Academy of Medical Sciences (FMedSci) in 2013 and is a National Institute of Health Research (NIHR) Senior Investigator. She received the Helmholtz International Fellow Award in 2014.
Professor Wedzicha has a major interest in the causes, mechanisms, impact and prevention of chronic obstructive pulmonary disease (COPD) exacerbations, and in the role of bacterial and viral infection in COPD exacerbations. She directs an active research group specializing in COPD exacerbations, and has published extensively on this topic.
Professor Wedzicha chaired the English Department of the Health Home Oxygen Clinical User Group, and was a member of the Guideline Development Group for the revision of the National Institute for Healthcare and Clinical Excellence COPD Guidelines. In 2016, she has been appointed as an Expert Adviser to the NICE Centre for Clinical Practice.
Professor Wedzicha was Editor-in-Chief of Thorax from 2002 to 2010, and is a member of the BioMed Central advisory board. She is currently Editor-in-Chief for the American Journal of Respiratory and Critical Care Medicine. In addition, she is on the editorial boards of a number of international journals. She was the Lancet Ombudsman till 2014, Publications Director for the European Respiratory Society (ERS) and has also previously been ERS Guidelines Director.
Professor of Medicine and Head of the Department for Pulmonary Medicine at the Philipps-University of Marburg, Marburg, Germany
Claus Vogelmeier is Professor of Medicine and Head of the Department for Pulmonary Medicine at the Philipps-University of Marburg, Germany. After qualifying in medicine from the University of Munich, Dr Vogelmeier started his professional career at the Hospital of the University of Munich.
He is board certified in Internal Medicine, in Pulmonary Medicine, in Cardiology and in Allergology. Dr Vogelmeier spent two years as a Postdoctoral Fellow at the Pulmonary Branch of the National Heart, Lung and Blood Institute, Institutes of Health in Bethesda, MD, USA. He was nominated Professor of Medicine at the Philipps-University of Marburg in 2001.
Claus Vogelmeier is an active member of several respiratory societies including the American Thoracic Society and the European Respiratory Society. From 2009 till 2011 he was president of the German Respiratory Society. Also in 2009 he became Chairman of the German Asthma and COPD Network. Since 2010 he is a member of the Science Committee and the Board of Directors of GOLD, since 2014 he serves as the chair of the Science Committee of GOLD. In 2014 he was awarded with the honorary title “Fellow of the European Respiratory Society”. Recently, he joined the editorial board of Lancet Respiratory Medicine. IN 2018 he was awarded with the honorary title “Fellow of the American Thoracic Society”.
He has a long-standing scientific and clinical interest in obstructive lung diseases with topics ranging from pathogenetic aspects to novel diagnostic methods and clinical studies. He has published around 350 scientific papers, reviews and book chapters, with numerous research articles in peer-reviewed journals including the New England Journal of Medicine, the American Journal of Respiratory and Critical Care Medicine, the Journal of Clinical Investigation, the European Respiratory Journal, Chest and Lancet Respiratory Medicine. He has lectured nationally and internationally at numerous scientific meetings and congresses.
Prof. Dr. Martin Möckel, FESC, FAHA
Charité-Universitätsmedizin Berlin, Germany
Martin Möckel is a Senior Physician, Professor of Cardiology and Head of Emergency Medicine and Acute Cardiovascular Care at Charité-Universitätsmedizin Berlin, Germany. His research focuses on biomarkers, health care research in Emergency and Acute Medicine, the application of interventional therapy in acute coronary care and he has led a number of multicentre trials. He is an Adjunct Professor at the James Cook University, School of Public Health and Epidemiology, Townsville, Australia.
Professor Möckel is joint Head of the Medical Apps Group for the German Cardiac Society. He is also a Fellow of the European Society of Cardiology, and an International Fellow of the American Heart Association.
Professor Möckel has delivered more than 200 oral and poster presentations at leading national and international conferences and has published extensively in the fields of emergency medicine, acute cardiac care and health care research. He is part of the biomarker core groups of the Acute Cardiovascular Care Association and the upcoming congress president 2019 of the German Society for Internal Intensive Care and Emergency Medicine.
Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK
Managing Director of Observational and Pragmatic Research Institute, Singapore
Managing Director of Optimum Patient Care, Australia, Singapore, and UK
Professor David Price is founder and head of The Observational and Pragmatic Research Institute (Singapore), an independent, research-driven organisation established to cultivate initiatives, provide evidence and drive quality standards within the growing field of real-life, pragmatic and observational research. This dynamic organisation delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in the United States, Europe and the Asia-Pacific region, such as Singapore, South Korea, Taiwan, The Philippines, New Zealand, Australia, Japan and China. He is also head of Optimum Patient Care (Australia and UK), a science-based, social enterprise which focuses on disease registries and supporting care in primary and secondary care led by internationally recognised experts in all areas of respiratory medicine.
Professor Price established the Optimum Patient Care Research Database (OPCRD; http://opcrd.co.uk/), one of the largest enhanced healthcare databases holding anonymous data from over 650 general practices and approximately 5.3 million patients in the UK. He currently leads the first International Severe Asthma Registry (ISAR; http://isaregistries.org/) by creating a consortium of world leaders at the forefront of severe asthma research from over 20 countries. His efforts have unified the severe asthma world by creating a vibrant space to exchange ideas and by standardising the data fields across countries, which is enabling data to be pooled and shared.
Professor Price is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). He was awarded Fellow of ERS (FERS) in 2016. He is also a member of the World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma (ARIA) executive committee, the World Allergy Organization (WAO) Committee on Asthma, and the WAO Education Council.
Professor Price was the founding president of the Respiratory Effectiveness Group (http://www.effectivenessevaluation.org/), a not-for-profit, investigator-led initiative which uses an international collaborative approach to explore the optimum role of real-life research in informing clinical guidelines and improving patient care.
Professor Price completed his medical degree at Cambridge University in 1984. He was previously Affiliate Associate Professor in the Department of General Practice at the University of Adelaide, Australia and held an Honorary Chair at the University of East Anglia, UK.
He is extensively involved in respiratory and allergy research; his areas of special interest are the ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, adherence, and patient attitudes to their disease. He has authored over 450 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. He is currently Editor-in-Chief of the journal Pragmatic and Observational Research and a member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.
Professor and Chair of Behavioral Medicine, Dept. of Psychology, University of Quebec at Montreal (UQAM)
Co-Director, Montreal Behavioral Medicine Center (MBMC)
Researcher, Chronic Disease Research Division, Hôpital du Sacre-Coeur de Montreal
Chair, Health Psychology, Canadian Psychological Association
Member, College of the Royal Society of Canada
Dr. Lavoie is Full Professor and Chair of Behavioral Medicine in the Dept. of Psychology, at the University of Quebec at Montreal (UQAM), Former Director of the Chronic Disease Research Division at Hôpital du Sacre-Coeur de Montreal, and Co-Director of the Montreal Behavioral Medicine Center. She holds a number of national and international leadership positions including Co-Lead of the International Behavioral Trials Network and Chair of the Canadian Network for Health Behavior Change. Dr. Lavoie is internationally recognized for her research on chronic disease prevention and the impact of behavioral interventions, such as motivational communication, on health behaviors and chronic disease outcomes. She has held more than $20 million in grant funding and has authored over 150 peer-reviewed papers and book chapters. Dr. Lavoie is highly sought out to design and deliver health behavior change interventions, with a focus on motivational communication, where to date, over 10,000 health professionals worldwide have attended her workshops.